This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
On August 26, 2022, Moderna released a press statement that they will pursue a patentinfringement lawsuit against Pfizer/BioNTech for their use of Moderna’s registered mRNA patents in creating the Pfizer COVID-19 mRNA vaccine. Moderna claimed that they had registered foundational mRNA patents between 2010 and 2016.
Moderna recently sued Pfizer alleging patentinfringement of three out of eight patents that cover its Covid 19 vaccine (Spikevax). Moderna’s patentinfringement lawsuit is a revenue seeking activity since Moderna wants fair compensation but does not want to remove Comirnaty from the market. Image from here.
Additionally, if you are a patent owner or inventor, please include the number of U.S. and foreign patent applications you have filed; the number of U.S. Commenters need not respond to every question and may provide relevant information even if not responsive to a particular question.
The case arises out of a 2018 lawsuit, in which four self-described inventors of DNA Arrays brought suit against Illumina, a “multibillion-dollar, global player in genetic analysis,” alleging that Illumina and its associates conspired to steal Petitioner’s trade secrets and covertly conceal the information in patent applications.
2:21-cv-00126-JRG-RSP) (not available on line for free from what I can see) addressed an accused infringer’s argument that the assignment of the patent-in-suit from the sole inventor (Afana) to the plaintiff, Mobile Equity, was ineffective, and so the patentee lacked standing. Walmart (Case No. Taylor Made Plastics, Inc.,
PureCircle sued SweeGen for patentinfringement back in 2018, asserting U.S. Patent Nos. The patents here claim a method of making Rebaudioside X. 112(a) and requires a patent specification to demonstrate the inventor actually possessed the full scope of the claimed invention at the time of filing.
Samsung argued that there were potential witnesses from non-party Samsung Research America (“SRA”), three of the five named inventors, prosecution counsel for the patents, and third-party AliphCom in the NDCA. Mercedes-Benz USA, LLC, 2:21-cv-00454 (E.D. September 11, 2022) (Roy Payne). defendant (“Holdings”). Samsung Electronics Co.,
Background Trinity sued Covalent for patentinfringement of U.S. Patent 9,087,321 (“the ’321 patent”) and U.S. Patent 10,936,685 (“the ’685 patent”) (collectively, “the challenged patents”). 61/309,038, filed on March 1, 2010.
In 2010, Rae graduated from the University of Texas with a B.S. In 2010, he graduated from the Georgia Institute of Technology with a B.S. Joy Kete litigates multimillion-dollar global patent disputes in U.S. April Park assists her clients with all aspects of patentinfringement matters before the U.S. in biology.
Since the BPCIA’s enactment in 2010, 50 BPCIA cases have been filed in district courts. ( Patentinfringement. PatentInfringement. Both patentinfringement cases (-2258, -2899) remain ongoing. See Figure 2.) adalimumab). Alvotech USA et al. 1:21-cv-05645). adalimumab). Declaratory judgment.
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content